Literature DB >> 31402215

Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia.

Marissa J Kilberg1, Saba Sheikh2, Darko Stefanovski3, Christina Kubrak2, Diva D De Leon4, Denis Hadjiliadis5, Ronald C Rubenstein2, Michael R Rickels6, Andrea Kelly4.   

Abstract

BACKGROUND: Post-prandial and oral glucose tolerance test-related hypoglycemia is common in cystic fibrosis (CF); however, the underlying mechanisms are unclear.
METHODS: To understand the relationship of hypoglycemia with meal-related glucose excursion and insulin secretion, we analyzed plasma glucose, insulin, C-peptide, glucagon and incretins obtained during standardized mixed-meal tolerance tests (MMTT) in non-diabetic adolescents and young adults with pancreatic insufficient CF (PI-CF).
RESULTS: Hypoglycemia, defined as glucose <70 mg/dL, occurred in 9/34 subjects at 150 (range:120-210) minutes following initial meal ingestion. Hypoglycemia[+] and hypoglycemia[-] groups did not differ in gender, age, lung function, HbA1c, or BMI. While 11/14 hypoglycemia[-] individuals displayed normal glucose tolerance (NGT), only 2/9 hypoglycemia[+] had NGT. Peak glucose was higher in hypoglycemia[+] vs hypoglycemia[-]. Compared to hypoglycemia[-] NGT, hypoglycemia[+] exhibited lower early-phase insulin secretion (ISR-AUC0-30min). ISR-AUC120-180min was not different in hypoglycemia[+] vs hypoglycemia[-] with abnormal glucose tolerance (AGT); however, glucose-AUC120-180min was lower in hypoglycemia[+] vs hypoglycemia[-] AGT. After adjusting for glucose-AUC, hypoglycemia[+] subjects tended to have higher ISR-AUC120-180min than hypoglycemia[-] AGT. Glucagon concentration did not differ between groups. Lower GLP-1-AUC30min and AUC180min and higher GIP-AUC30min were present in hypoglycemia[+] individuals.
CONCLUSION: Hypoglycemia is common in PI-CF following MMTT and is associated with early glucose dysregulation (higher peak glucose), more impaired early-phase insulin secretion (lower ISR-AUC30min), and possibly late compensatory hyperinsulinemia. Further study is required to understand whether absence of glucagon difference in the hypoglycemia[+] individuals signals counterregulatory impairment, to delineate the role of incretins in hypoglycemia, and to determine the relationship of hypoglycemia to emergence of CFRD.
Copyright © 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Glucose tolerance; Hypoglycemia; Insulin secretion; Pancreatic insufficiency

Mesh:

Substances:

Year:  2019        PMID: 31402215      PMCID: PMC7007375          DOI: 10.1016/j.jcf.2019.07.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  29 in total

1.  Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity.

Authors:  E Breda; M K Cavaghan; G Toffolo; K S Polonsky; C Cobelli
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

2.  Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.

Authors:  Cristina Bianchi; Roberto Miccoli; Maddalena Trombetta; Francesco Giorgino; Simona Frontoni; Emanuela Faloia; Giulio Marchesini; Maria A Dolci; Franco Cavalot; Gisella Cavallo; Frida Leonetti; Riccardo C Bonadonna; Stefano Del Prato
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

3.  Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females.

Authors:  Belma Haliloglu; Yasemin Gokdemir; Zeynep Atay; Saygin Abali; Tulay Guran; Fazilet Karakoc; Refika Ersu; Bulent Karadag; Serap Turan; Abdullah Bereket
Journal:  Pediatr Diabetes       Date:  2016-11-22       Impact factor: 4.866

4.  One-hour post-load plasma glucose level during the OGTT predicts dysglycemia: Observations from the 24year follow-up of the Israel Study of Glucose Intolerance, Obesity and Hypertension.

Authors:  Michael Bergman; Angela Chetrit; Jesse Roth; Ram Jagannathan; Mary Sevick; Rachel Dankner
Journal:  Diabetes Res Clin Pract       Date:  2016-08-26       Impact factor: 5.602

5.  Cystic fibrosis-related diabetes is caused by islet loss and inflammation.

Authors:  Nathaniel J Hart; Radhika Aramandla; Gregory Poffenberger; Cody Fayolle; Ariel H Thames; Austin Bautista; Aliya F Spigelman; Jenny Aurielle B Babon; Megan E DeNicola; Prasanna K Dadi; William S Bush; Appakalai N Balamurugan; Marcela Brissova; Chunhua Dai; Nripesh Prasad; Rita Bottino; David A Jacobson; Mitchell L Drumm; Sally C Kent; Patrick E MacDonald; Alvin C Powers
Journal:  JCI Insight       Date:  2018-04-19

6.  Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.

Authors:  R W Holl; E Heinze; A Wolf; M Rank; W M Teller
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

7.  Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication.

Authors:  Andrew A Palladino; Samir Sayed; Lorraine E Levitt Katz; Paul R Gallagher; Diva D De León
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

Review 8.  Hypoglycaemia in cystic fibrosis in the absence of diabetes: A systematic review.

Authors:  N Armaghanian; J C Brand-Miller; T P Markovic; K S Steinbeck
Journal:  J Cyst Fibros       Date:  2016-03-22       Impact factor: 5.482

9.  Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Authors:  Kirsten Vollmer; Jens J Holst; Birgit Baller; Mark Ellrichmann; Michael A Nauck; Wolfgang E Schmidt; Juris J Meier
Journal:  Diabetes       Date:  2007-12-05       Impact factor: 9.461

10.  Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes.

Authors:  Kerstin Radike; Katharina Molz; Reinhard W Holl; Britta Poeter; Helge Hebestreit; Manfred Ballmann
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

View more
  5 in total

1.  Hypoglycemia and Islet Dysfunction Following Oral Glucose Tolerance Testing in Pancreatic-Insufficient Cystic Fibrosis.

Authors:  Marissa J Kilberg; Clea Harris; Saba Sheikh; Darko Stefanovski; Marina Cuchel; Christina Kubrak; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

2.  Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis.

Authors:  Moira L Aitken; Magdalena A Szkudlinska; Edward J Boyko; Debbie Ng; Kristina M Utzschneider; Steven E Kahn
Journal:  Diabetologia       Date:  2020-01-29       Impact factor: 10.122

Review 3.  Overview of Atypical Diabetes.

Authors:  Jaclyn Tamaroff; Marissa Kilberg; Sara E Pinney; Shana McCormack
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-14       Impact factor: 4.741

4.  Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems.

Authors:  Brynn E Marks; Kristen M Williams; Jordan S Sherwood; Melissa S Putman
Journal:  J Clin Transl Endocrinol       Date:  2021-12-04

5.  Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis.

Authors:  Wang Shin Lei; Marissa J Kilberg; Babette S Zemel; Ronald C Rubenstein; Clea Harris; Saba Sheikh; Andrea Kelly; Joseph M Kindler
Journal:  J Clin Transl Endocrinol       Date:  2022-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.